• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.

作者信息

Pardanani A, Gotlib J, Roberts A W, Wadleigh M, Sirhan S, Kawashima J, Maltzman J A, Shao L, Gupta V, Tefferi A

机构信息

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Stanford Cancer Institute, Stanford, CA, USA.

出版信息

Leukemia. 2018 Apr;32(4):1035-1038. doi: 10.1038/leu.2017.330. Epub 2017 Nov 16.

DOI:10.1038/leu.2017.330
PMID:29263442
Abstract
摘要

相似文献

1
Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis.JAK1和JAK2抑制剂莫洛替尼治疗骨髓纤维化的长期疗效和安全性
Leukemia. 2018 Apr;32(4):1035-1038. doi: 10.1038/leu.2017.330. Epub 2017 Nov 16.
2
Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia.莫洛替尼治疗骨髓纤维化：一种在治疗和理解贫血方面具有作用的JAK1/2抑制剂。
Future Oncol. 2017 Feb;13(5):395-407. doi: 10.2217/fon-2016-0417. Epub 2016 Oct 27.
3
Myelofibrosis, JAK2 inhibitors and erythropoiesis.骨髓纤维化、JAK2抑制剂与红细胞生成
Leukemia. 2013 Jun;27(6):1219-23. doi: 10.1038/leu.2013.72.
4
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.莫米松替比 versus 持续芦可替尼或 JAK 抑制剂治疗经验的骨髓纤维化伴贫血患者的最佳可用治疗：SIMPLIFY-2 的亚组分析。
Adv Ther. 2024 Sep;41(9):3722-3735. doi: 10.1007/s12325-024-02928-4. Epub 2024 Jul 11.
5
A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia.一项针对强效JAK1和JAK2抑制剂莫洛替尼治疗真性红细胞增多症或原发性血小板增多症患者的2期研究。
Leuk Res. 2017 Sep;60:11-17. doi: 10.1016/j.leukres.2017.05.002. Epub 2017 May 30.
6
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.SIMPLIFY-1 试验中根据基线血红蛋白水平的骨髓纤维化患者亚组中的 Momelotinib 与 Ruxolitinib 的比较。
Leuk Lymphoma. 2024 Jul;65(7):965-977. doi: 10.1080/10428194.2024.2328800. Epub 2024 Mar 19.
7
Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.Momelotinib治疗引发的神经病变：100例骨髓纤维化患者的患病率、危险因素及转归
Br J Haematol. 2015 Apr;169(1):77-80. doi: 10.1111/bjh.13262. Epub 2014 Dec 15.
8
How many JAK inhibitors in myelofibrosis?骨髓纤维化中有多少种JAK抑制剂？
Best Pract Res Clin Haematol. 2014 Jun;27(2):187-95. doi: 10.1016/j.beha.2014.07.010. Epub 2014 Jul 18.
9
Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.莫洛替尼治疗的骨髓纤维化患者反应和生存的遗传决定因素。
Leukemia. 2015 Mar;29(3):741-4. doi: 10.1038/leu.2014.306. Epub 2014 Nov 11.
10
Momelotinib: Mechanism of action, clinical, and translational science.莫雷洛替尼：作用机制、临床和转化科学。
Clin Transl Sci. 2024 Aug;17(8):e70018. doi: 10.1111/cts.70018.

引用本文的文献

1
Efficacy and Safety of Momelotinib in Myelofibrosis: A Systematic Review and Meta-Analysis With a Focus on Anemia Outcomes.莫洛替尼治疗骨髓纤维化的疗效与安全性：一项聚焦贫血结局的系统评价和荟萃分析
J Hematol. 2025 Aug 25;14(4):214-222. doi: 10.14740/jh2094. eCollection 2025 Aug.
2
The Immune Microenvironment: New Therapeutic Implications in Organ Fibrosis.免疫微环境：器官纤维化中的新治疗意义
Adv Sci (Weinh). 2025 Aug;12(30):e05067. doi: 10.1002/advs.202505067. Epub 2025 May 20.
3
Momelotinib in JAK2 inhibitor-naïve myelofibrosis: pros and cons.

本文引用的文献

1
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.SIMPLIFY-1：一项在初治的骨髓纤维化患者中比较莫洛替尼与芦可替尼的III期随机试验。
J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20.
2
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.一项1/2期开放标签研究，评估莫洛替尼每日两次给药治疗骨髓纤维化的效果。
Haematologica. 2017 Jan;102(1):94-102. doi: 10.3324/haematol.2016.148924. Epub 2016 Sep 15.
3
Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib.
初治的骨髓纤维化患者使用莫洛替尼：利弊分析
Blood Cancer J. 2025 May 7;15(1):91. doi: 10.1038/s41408-025-01302-z.
4
Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial.盐酸杰克替尼片治疗活动性中轴型脊柱关节炎的疗效和安全性：一项多中心、随机、双盲、安慰剂对照的II期临床试验
RMD Open. 2025 Jan 2;11(1):e004865. doi: 10.1136/rmdopen-2024-004865.
5
How I individualize selection of JAK inhibitors for patients with myelofibrosis.我如何为骨髓纤维化患者个体化选择JAK抑制剂。
Blood. 2025 Apr 17;145(16):1724-1737. doi: 10.1182/blood.2023022415.
6
Momelotinib in myelofibrosis and beyond: a comprehensive review of therapeutic insights in hematologic malignancies.莫洛替尼在骨髓纤维化及其他病症中的应用：血液系统恶性肿瘤治疗见解的全面综述
Discov Oncol. 2024 Aug 27;15(1):370. doi: 10.1007/s12672-024-01252-1.
7
Momelotinib for the treatment of myelofibrosis.莫雷洛替尼治疗骨髓纤维化。
Blood. 2024 Aug 15;144(7):708-713. doi: 10.1182/blood.2023023719.
8
Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant.骨髓纤维化中Calr 1型/类突变是莫洛替尼药物生存期及非移植情况下长期生存的最显著预测指标。
Blood Cancer J. 2024 Mar 19;14(1):51. doi: 10.1038/s41408-024-01028-4.
9
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval.Momelotinib用于治疗骨髓纤维化：我们对100例临床试验患者的14年经验及美国食品药品监督管理局近期的批准。
Blood Cancer J. 2024 Mar 18;14(1):47. doi: 10.1038/s41408-024-01029-3.
10
Discovery of novel JAK1 inhibitors through combining machine learning, structure-based pharmacophore modeling and bio-evaluation.通过机器学习、基于结构的药效团模型构建和生物评估相结合发现新型 JAK1 抑制剂。
J Transl Med. 2023 Aug 28;21(1):579. doi: 10.1186/s12967-023-04443-6.
对111例接受莫洛替尼或芦可替尼治疗的骨髓纤维化患者的缓解情况和长期停药率的修订评估。
Leukemia. 2015 Feb;29(2):498-500. doi: 10.1038/leu.2014.286. Epub 2014 Sep 25.
4
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis.CYT387，一种 JAK1 和 JAK2 抑制剂，在骨髓纤维化中的安全性和疗效。
Leukemia. 2013 Jun;27(6):1322-7. doi: 10.1038/leu.2013.71. Epub 2013 Mar 5.
5
The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.新型 JAK 抑制剂 CYT387 可抑制多种信号通路，预防表型多样化骨髓瘤细胞的增殖并诱导其凋亡。
Leukemia. 2011 Dec;25(12):1891-9. doi: 10.1038/leu.2011.175. Epub 2011 Jul 26.
6
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.INCB018424，一种 JAK1 和 JAK2 抑制剂，在骨髓纤维化中的安全性和疗效。
N Engl J Med. 2010 Sep 16;363(12):1117-27. doi: 10.1056/NEJMoa1002028.
7
What are RBC-transfusion-dependence and -independence?什么是依赖输血和不依赖输血？
Leuk Res. 2011 Jan;35(1):8-11. doi: 10.1016/j.leukres.2010.07.015. Epub 2010 Aug 7.
8
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.CYT387，一种新型 JAK2 抑制剂，可诱导血液学反应并使小鼠骨髓增殖性肿瘤中的炎症细胞因子恢复正常。
Blood. 2010 Jun 24;115(25):5232-40. doi: 10.1182/blood-2009-05-223727. Epub 2010 Apr 12.
9
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.CYT387，一种选择性JAK1/JAK2抑制剂：激酶选择性的体外评估以及使用真性红细胞增多症患者的细胞系和原代细胞进行的临床前研究。
Leukemia. 2009 Aug;23(8):1441-5. doi: 10.1038/leu.2009.50. Epub 2009 Mar 19.
10
Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.骨髓增殖性肿瘤的分类与诊断：2008年世界卫生组织标准及即时诊断算法
Leukemia. 2008 Jan;22(1):14-22. doi: 10.1038/sj.leu.2404955. Epub 2007 Sep 20.